Compounds and compositions for treating conditions associated with sting activity
US-2024308978-A1 · Sep 19, 2024 · US
Indirubin derivatives, and uses thereof
US11524937B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11524937-B2 |
| Application number | US-201916594894-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 7, 2019 |
| Priority date | Feb 3, 2012 |
| Publication date | Dec 13, 2022 |
| Grant date | Dec 13, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a cancer or tumor in a subject comprising administering to the subject a therapeutically effective amount of an indirubin derivative (IRD) selected from the group consisting of IRD Nos. 9-13, 59, 61, 68-71, 79-87, 115, 124, 128 and 176, the cancer or tumor being selected from the group consisting of CML, prostate cancer, melanoma, pancreatic cancer, ovarian cancer, leukemia, and lymphoma 2. The method according to claim 1 , wherein the cancer is prostate cancer, and the indirubin derivative is selected from the group consisting of IRD Nos. 10-11, 13, 59, 71, 79, 80, 83, 84, 87, 128, and 176. 3. The method according to claim 1 , wherein the cancer is melanoma, and the indirubin derivative is selected from the group consisting of IRD Nos. 59, and 176. 4. The method according to claim 1 , wherein the cancer is pancreatic cancer, and the indirubin derivative is selected from the group consisting of IRD Nos. 9, 11, 13, 59, 61, 68-71, 82-87, 115, and 176. 5. The method according to claim 1 , wherein the cancer is ovarian cancer, and the indirubin derivative is selected from the group consisting of IRD Nos. 11, 13, 59, 61, 69, 71, 79-82, 84-87, 124, and 176. 6. The method according to claim 1 , wherein the cancer is leukemia, and the indirubin derivative is selected from the group consisting of IRD Nos. 10-13, 59, 61, 70, 71, 79-80, 83-87, 115, 128, and 176. 7. The method according to claim 1 , wherein the cancer is lymphoma, and the indirubin derivative is selected from the group consisting of IRD Nos. 10-13, 59, 79-80, 83, 84, 87, 115, 128, and 176. 8. A method of treating a condition regulated by a protein kinase in a subject comprising administering an indirubin derivative (IRD) selected from the group consisting of IRD Nos. 10, 11, 13, 61, 70, 71, 79, 80, 83-87, and 176, the protein kinase being selected from the group consisting of ABL1, ABL1 (T315I mutant), Aurora A, c-Src, FGR, FLT3, HCK, LYN, JAK2, and TYK2. 9. The method according to claim 1 , wherein the protein kinase is ABL1, and the indirubin derivative is selected from the group consisting of IRD Nos. 11, 13, 61, 70, 71, 79, 80, 83-87, and 176. 10. The method according to claim 1 , wherein the protein kinase is ABL1 (T315I mutant), and the indirubin derivative is selected from the group consisting of IRD Nos. 61, 79, 80, 83-85, and 87. 11. The method according to claim 1 , wherein the protein kinase is Aurora A, and the indirubin derivative is selected from the group consisting of IRD Nos.61, 70, 79, 80, 83-87, and 176. 12. The method according to claim 1 , wherein the protein kinase is c-Src, and the indirubin derivative is selected from the group consisting of IRD Nos. 10, 11, 13, 61, 70, 71, 79, 80, 83-87, and 176. 13. The method according to claim 1 , wherein the protein kinase is FGR, FLT3, HCK, LYN, or TYK2, and the indirubin derivative is IRD No. 176. 14. The method according to claim 1 , wherein the protein kinase is JAK2, and the indirubin derivative is selected from the group consisting of IRD Nos. 61, 79, 80, 83, 84, and 87.
Assignees
Inventors
Classifications
- C07D209/40Primary
Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11524937B2 cover?
- Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
- Who is the assignee on this patent?
- Hope City, The National And Kapodistrian Univ Of Athens
- What technology area does this patent fall under?
- Primary CPC classification C07D209/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).